Business Context and Reporting Period
Company: Bluejay Diagnostics, Inc. (BJDX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2024
Reporting Period: Immediate event reporting for transactions entered into on May 31, 2024, with closings expected on June 3, 2024.
Key Financial Metrics and Transaction Details
This filing reports the entry into material definitive agreements for short-term financing rather than periodic financial performance metrics (revenue, profit, or cash flow from operations are not disclosed in this document).
- Total Capital Raised: $2,000,000 in cash subscriptions.
- Instrument 1 (Note Purchase Agreement): $1,000,000 subscription for a senior secured note repayable at $1,176,470 (includes Original Issue Discount).
- Instrument 2 (Securities Purchase Agreement): $1,000,000 subscription for senior secured notes and 580,308 shares of common stock. Notes repayable at $1,111,110 (includes Original Issue Discount).
- Maturity Date: September 1, 2024.
- Security Interest: First lien and continuing first priority security interest in substantially all company assets.
- Interest: No accrual beyond OID unless an event of default occurs.
Material Changes and Obligations
The primary material change is the creation of a direct financial obligation and the issuance of unregistered equity securities.
- Refinancing Requirement: The Company must file a registration statement within 14 calendar days of closing and consummate a public financing transaction within 90 days of closing.
- Repayment Condition: 100% of net proceeds from the required public offering must be used to fully redeem and repay the notes within one business day of the offering's closing.
- Default Risk: Failure to file the registration statement or consummate the financing within the specified timelines constitutes an event of default.
Outlook, Risks, and Management Commentary
Management Commentary: The filing indicates an immediate need for liquidity and a strategic plan to bridge to a public offering. Aegis Capital Corp. served as the placement agent.
Risks and Contingencies:
- Liquidity Risk: The company is reliant on a successful public offering within 90 days to repay the current debt.
- Asset Encumbrance: Substantially all assets are now pledged as collateral for the new notes.
- Equity Dilution: Immediate issuance of 580,308 shares of common stock.
Investor Verification Checklist
- Verify the status of the registration statement filing (required within 14 days of June 3, 2024).
- Monitor progress toward consummating a public financing transaction by late August 2024 (90-day deadline).
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific default triggers and covenants.
- Assess the company's current cash runway relative to the September 1, 2024 maturity date.